OxyPrem AG receives CHF 2.2 million to further accelerated their technology. This direct funding by SERI enables cutting-edge innovation based on scientific excellence that has proven itself in international competition.
OxyPrem AG receives CHF 2.2 million to further accelerated their technology. This direct funding by SERI enables cutting-edge innovation based on scientific excellence that has proven itself in international competition.
For newsletter distribution, your email address will be processed by a GDPR-certified service provider. Further information can be found in our privacy policy.